Cargando…

Risk Factors for Acquired Rifamycin and Isoniazid Resistance: A Systematic Review and Meta-Analysis

BACKGROUND: Studies looking at acquired drug resistance (ADR) are diverse with respect to geographical distribution, HIV co-infection rates, retreatment status and programmatic factors such as regimens administered and directly observed therapy. Our objective was to examine and consolidate evidence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rockwood, Neesha, Abdullahi, Leila H., Wilkinson, Robert J., Meintjes, Graeme
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583446/ https://www.ncbi.nlm.nih.gov/pubmed/26406228 http://dx.doi.org/10.1371/journal.pone.0139017

Ejemplares similares

Correction: Risk Factors for Acquired Rifamycin and Isoniazid Resistance: A Systematic Review and Meta-Analysis
Publicado: (2015)

Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence
por: Rockwood, Neesha, et al.
Publicado: (2017)

HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients
por: Rockwood, Neesha, et al.
Publicado: (2016)

Use of Isoniazid Monotherapy in Comparison to Rifamycin-Based Regimen for the Treatment of Patients With Latent Tuberculosis: A Systematic Review
por: Shahid, Noor ul ain, et al.
Publicado: (2022)

Utility of Second-Generation Line Probe Assay (Hain MTBDRplus) Directly on 2-Month Sputum Specimens for Monitoring Tuberculosis Treatment Response
por: Rockwood, Neesha, et al.
Publicado: (2017)

Generation of Tetracycline and Rifamycin Resistant Chlamydia Suis Recombinants
por: Marti, Hanna, et al.
Publicado: (2021)

Characterization of the Rifamycin-Degrading Monooxygenase From Rifamycin Producers Implicating Its Involvement in Saliniketal Biosynthesis
por: Zheng, Xiao-Fu, et al.
Publicado: (2020)

Redesign of Rifamycin Antibiotics to Overcome ADP‐Ribosylation‐Mediated Resistance
por: Lan, Tian, et al.
Publicado: (2022)

Deciphering the late steps of rifamycin biosynthesis
por: Qi, Feifei, et al.
Publicado: (2018)

Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis
por: Rockwood, Neesha, et al.
Publicado: (2017)

Study on Dissolution Thermodynamics and Cooling Crystallization of Rifamycin S
por: Chen, Kui, et al.
Publicado: (2021)

Rifamycin O, An Alternative Anti-Mycobacterium abscessus Agent
por: Hanh, Bui Thi Bich, et al.
Publicado: (2020)

Stability of Non-Ionic Surfactant Vesicles Loaded with Rifamycin S
por: Marchianò, Verdiana, et al.
Publicado: (2022)

Kanglemycin A Can Overcome Rifamycin Resistance Caused by ADP-Ribosylation by Arr Protein
por: Harbottle, John, et al.
Publicado: (2021)

Promise and Peril of Pretomanid–Rifamycin Regimens for Drug-susceptible Tuberculosis
por: Velásquez, Gustavo E., et al.
Publicado: (2023)

Blocking ADP-ribosylation expands the anti-mycobacterial spectrum of rifamycins
por: Ganapathy, Uday S., et al.
Publicado: (2023)

Acquired Resistance to Isoniazid During Isoniazid Monotherapy in a Subject with Latent Infection Following Household Rifampicin-Resistant Tuberculosis Contact: A Case Report
por: Li, Tsung-Lun, et al.
Publicado: (2021)

Effect of Genetic Variations in Drug-Metabolizing Enzymes and Drug Transporters on the Pharmacokinetics of Rifamycins: A Systematic Review
por: Sileshi, Tesemma, et al.
Publicado: (2022)

Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanism
por: Peek, James, et al.
Publicado: (2018)

Poor treatment outcome and associated risk factors among patients with isoniazid mono-resistant tuberculosis: A systematic review and meta-analysis
por: Alemu, Ayinalem, et al.
Publicado: (2023)

Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies.
por: Strolin Benedetti, M, et al.
Publicado: (1994)

Isoniazid Preventive Therapy and Risk for Resistant Tuberculosis
por: Balcells, Maria Elvira, et al.
Publicado: (2006)

Draft Genome Sequence of the Rifamycin Producer Amycolatopsis rifamycinica DSM 46095
por: Saxena, Anjali, et al.
Publicado: (2014)

Pharmacokinetic Drug Interactions of Antimicrobial Drugs: A Systematic Review on Oxazolidinones, Rifamycines, Macrolides, Fluoroquinolones, and Beta-Lactams
por: Bolhuis, Mathieu S., et al.
Publicado: (2011)

Rifamycin SV-MMX® as the recommended self-treatment for moderate to severe travellers’ diarrhoea: reply
por: Steffen, Robert, et al.
Publicado: (2019)

Comparison of Rifamycins for Efficacy Against Mycobacterium avium Complex and Resistance Emergence in the Hollow Fiber Model System
por: Boorgula, Gunavanthi D., et al.
Publicado: (2021)

Rifamycin SV-MMX(®) for treatment of travellers’ diarrhea: equally effective as ciprofloxacin and not associated with the acquisition of multi-drug resistant bacteria
por: Steffen, Robert, et al.
Publicado: (2018)

Prevalence of Mycobacterium tuberculosis mutations associated with isoniazid and rifampicin resistance: A systematic review and meta-analysis
por: Rostamian, Mosayeb, et al.
Publicado: (2023)

Inflammatory profile of patients with tuberculosis with or without HIV-1 co-infection: a prospective cohort study and immunological network analysis
por: Bruyn, Elsa Du, et al.
Publicado: (2021)

Integrative metagenomic and biochemical studies on rifamycin ADP-ribosyltransferases discovered in the sediment microbiome
por: Shin, Jae Hong, et al.
Publicado: (2018)

Hepatocytic transcriptional signatures predict comparative drug interaction potential of rifamycin antibiotics
por: Dyavar, Shetty Ravi, et al.
Publicado: (2020)

C25-modified rifamycin derivatives with improved activity against Mycobacterium abscessus
por: Paulowski, Laura, et al.
Publicado: (2022)

State of the Art on Developments of (Bio)Sensors and Analytical Methods for Rifamycin Antibiotics Determination
por: Noor, Hassan, et al.
Publicado: (2023)

An in silico analysis of rpoB mutations to affect Chlamydia trachomatis sensitivity to rifamycin
por: Benamri, Ichrak, et al.
Publicado: (2022)

Impact of Isoniazid Resistance-Conferring Mutations on the Clinical Presentation of Isoniazid Monoresistant Tuberculosis
por: Dantes, Raymund, et al.
Publicado: (2012)

What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis
por: Stagg, H R, et al.
Publicado: (2016)

8-Deoxy-Rifamycin Derivatives from Amycolatopsis mediterranei S699 ΔrifT Strain
por: Ye, Feng, et al.
Publicado: (2020)

Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis
por: Thai, Phan Vuong Khac, et al.
Publicado: (2018)

Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis: A Systematic Review
por: Seifert, Marva, et al.
Publicado: (2015)

Treatment of isoniazid-resistant pulmonary tuberculosis
por: Kim, Yee Hyung, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_mnnhreqme4u2l79glcu4iorec5